Хемоктин (Human Coagulation Factor Viii)

Хемоктин is a human coagulation factor VIII product used to manage bleeding in hemophilia A. This intravenous therapy supports clotting factor replacement for patients with factor VIII deficiency. Suitable for routine prophylaxis and on-demand treatment of bleeding episodes.

Хемоктин is primarily used to treat and prevent bleeding episodes in patients with hemophilia A, a genetic disorder causing factor VIII deficiency. It may also be used for perioperative management to reduce bleeding risk during surgical procedures. The therapy helps restore normal clotting function by replacing the missing or defective factor VIII protein.

Хемоктин works by temporarily increasing factor VIII levels in the bloodstream, which helps form stable blood clots and reduces bleeding episodes. Patients may experience improved clotting function shortly after administration, supporting daily activities and reducing spontaneous bleeding risks. Individual responses may vary based on dosing and underlying condition.

Хемоктин should be handled with care to avoid contamination or infection. It is intended for intravenous use only and must be prepared and administered by trained healthcare professionals. Patients should be monitored for signs of allergic reactions or infusion-related issues during and after administration.

Хемоктин may interact with other medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. Patients should inform their healthcare provider about all current medications, including over-the-counter products and supplements. No specific drug interactions are widely documented, but caution is advised when combining with other hemostatic agents.